Candel Therapeutics, Inc.
CADL
$5.81
$0.101.75%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -165.00% | 152.43% | -32.19% | 52.12% | -170.49% |
Total Depreciation and Amortization | -1.22% | 0.00% | 0.00% | -1.61% | -0.80% |
Total Amortization of Deferred Charges | -27.27% | -15.38% | -16.13% | -15.07% | -12.05% |
Total Other Non-Cash Items | 69.32% | -300.29% | 147.06% | -80.87% | 1,250.66% |
Change in Net Operating Assets | 103.67% | -345.63% | -11.97% | 91.38% | 126.22% |
Cash from Operations | -3.19% | -48.19% | 11.55% | -6.05% | 26.55% |
Capital Expenditure | -933.33% | 0.00% | -- | 100.00% | 14.29% |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | -933.33% | 0.00% | -- | 100.00% | 14.29% |
Total Debt Issued | -- | -- | -- | -- | -- |
Total Debt Repaid | 0.00% | 0.00% | 0.00% | 0.00% | -49.97% |
Issuance of Common Stock | 3,065.71% | -99.33% | 2,160.31% | -6.03% | 978.88% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | -- | -- | -- | -- | -- |
Cash from Financing | 1,032.83% | -102.03% | 5,380.80% | -13.78% | 254.98% |
Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | 181.25% | -112.18% | 1,858.50% | -14.96% | 56.09% |